Durin Life Sciences

Durin Life Sciences is a biotechnology company specializing in the development of high accuracy, minimally invasive blood-based diagnostic tests—branded as "Duritect™"—for the early detection of neurodegenerative disorders such as Alzheimer's and Parkinson's. The company's proprietary platform leverages immune system autoantibodies combined with advanced machine learning algorithms. In clinical studies presented at major conferences like AAIC 2024, their lead product demonstrated industry-leading accuracy among blood-based biomarkers. The company holds over twenty patents related to its technology and has raised more than $15 million to date. Its first commercial launches are scheduled for 2025.